The mention of Piramal could bring back memories of its deal with Abbott India, when Piramal Healthcare sold its formulation business for about Rs 17,000 crore. A lot has changed since and the Street’s interest in Piramal Enterprise’s stock, too, gradually receded.
For instance, Sarabjit Kour Nangra, vice-president of Research, Angel Broking, who had an active coverage on Piramal Healthcare says after the sale, the residual businesses were only cash and contract research and manufacturing. So, not many analysts tracked it.
However, the firm’s journey after its name changed to Piramal Enterprise (PEL) is interesting. PEL’s stock, which was trading at Rs 500-550 levels in 2012, is now at Rs 1,877 and commands a market capitalisation of around Rs 32,000 crore. Much of the stock re-rating has happened in the past seven months, where it has more than doubled on hopes of gains emerging from value-unlocking of businesses like financials.
Work is on to demerge its health care and financial services businesses. On Tuesday, PEL made further progress on this by transferring assets to its wholly-owned finance subsidiary for a net consideration of around Rs 1,500 crore. While this is positive, analysts say more clarity and faster pace of restructuring is required.
“We don’t know how net worth has been allocated to each of its business and this makes valuations complex for PEL,” says an analyst from a domestic brokerage. “Therefore, business reorganisation is extremely critical to renew interest in the stock,” he points out.